Hammered by a series of setbacks, NewLink axes staff (again) and circles its wagons around troubled IDO program
Three months after NewLink Genetics scrapped a combination program for its IDO pathway drug indoximod in the general rout that followed the failure of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.